Dengue and Platelet Transfusion: Assessing the Appropriateness and Clinical Outcomes

Abstract

Introduction

Dengue is caused by the Dengue virus, an arboviral infection (Kurukularatne et al. 2011) seen world wide, especially along the tropical and subtropical countries (Gupta et al. 2012). It is transmitted among humans through the bite of female mosquitoes of Aedes aegypti species (Whitehorn and Farrar 2010). Dengue virus comes under the Flaviviridae family with four different serotypes, which are referred to as DV-1, DV-2, DV-3 and DV-4(Liker et al. 2022). Dengue is endemic in around 100 countries world wide (Hill-Strathy et al. 2021). The incidence of Dengue has been increasing globally (Thrombocytopenia and Platelet Transfusions in Dengue Haemorrhagic Fever and Dengue Shock Syndrome, n.d.) ,  with Southeast Asian countries, which include India, Indonesia, Thailand and Myanmar, accounting for the majority of global incidence. Contributing factors for this are population growth, urbanization and inadequate water management, which leads to mosquito proliferation (Shivbalan et al. 2004). As per the National Vector Borne Disease Control Program of India, case detection and vector control still remain important strategies for prevention and spread of the virus (Kurukularatne et al. 2011).